

Stephania delavayi Diels. inhibits breast carcinoma proliferation through the p38 MAPK/NF- κ B/COX-2 pathway

DAE-HUN PARK^{1*}, HONG DE XU^{2*}, JAEGAL SHIM^{3*}, YONG-CHUN LI⁴, JONG-HWA LEE¹,
SOON-CHANG CHO⁵, SANG-SEOP HAN⁶, YUN LYUL LEE⁷, MIN-JAE LEE⁴ and SUNG-WON KWON⁸

¹Toxicology Center, Korea Institute of Toxicology, Yuseong, Daejeon 305-343, Republic of Korea; ²School of Pharmaceutical Science, Zhengzhou University, Zhengzhou 4500001, P.R. China; ³Cancer Experimental Resources Branch, National Cancer Center, Ilsandong-gu, Goyang-si, Gyeonggi-do 410-769; ⁴School of Veterinary Medicine, Kangwon National University, Chuncheon-si, Gangwon-do 200-701; ⁵Center for Senior Industry, Youngdong University, Yeongdong-gun, Chungnam 370-701; ⁶Hoseo University, Baebang-myun, Asan-si, Chungnam 336-79; ⁷Department of Physiology, College of Medicine, Hallym University, Chuncheon-si, Gangwon-do, 200-70; ⁸CHA Bundang Medical Center, CHA University, Bundang-gu, Seongnam-si, Gyeonggi-do 463-712, Republic of Korea

Received March 4, 2011; Accepted April 20, 2011

DOI: 10.3892/or.2011.1364

Abstract. The nuclear factor κ B (NF- κ B)/inhibitor of κ kinase- β (IKK β) signaling pathway is important in tumor promotion and progression. MDA-MB-231 human breast carcinoma cells express COX-2 and show a constitutive phosphorylation of NF- κ B. Many non-specific inhibitors of IKK β and NF- κ B are used to inhibit tumor promotion and progression. The *Stephania delavayi* Diels. (*S. delavayi* Diels.) extract has been reported to safely activate B cell immunity and there is evidence suggesting that it may be a promising new anticancer therapeutic agent. *S. delavayi* Diels. extract suppressed proliferation of the breast cancer cell lines MDA-MB-231 and MCF-7 by inducing cell death. To aid in the development of the *S. delavayi* Diels. extract as a therapeutic agent, its mechanisms of action were investigated, in particular its effects on p38 MAPK, NF- κ B and COX-2, which play important roles in inflammation and cancer. *S. delavayi* Diels. stimulated p38 MAPK phosphorylation but reduced NF- κ B phosphorylation and COX-2 expression in a dose- and time-dependent manner. Thus, *S. delavayi* Diels., which appears to

act primarily through p38 MAPK/NF- κ B/COX-2 signaling in breast carcinomas, may be a potent anticancer agent with target specificity and low toxicity.

Introduction

MAPKs play key roles in mediating the effects of various extracellular stimuli and intracellular responses. Three MAPKs have been identified in mammalian cells: ERKs, JNKs, and p38 kinase (p38 MAPK). Each MAPK is activated by different stimuli and regulates different downstream targets (1). In particular, p38 MAPK is stimulated by UV irradiation, osmotic stress, and cytokines such as tumor necrosis factor- α (TNF- α) and interleukin-1 β (IL-1 β) (1,2).

The nuclear factor κ B (NF- κ B)/inhibitor of κ kinase- β (IKK β) signaling pathway is important in tumor promotion and progression (3). When activated, the transcription factor NF- κ B inhibits apoptosis (4), induces G1/S phase transition by up-regulating the expression of cyclin D1 (5) and COX-2 (6). In MDA-MB-231 human breast carcinoma cells, NF- κ B and inhibitor of κ B (IkB) are constitutively phosphorylated (7) and COX-2 expression is observed (8). Many non-specific inhibitors of IKK β and NF- κ B are used to inhibit tumor promotion and progression. These agents include anti-inflammatory drugs, such as sulphasalazine and trans-resveratrol, and non-steroidal anti-inflammatory drugs, such as aspirin, sulindac sulphide, cyclopentenone prostaglandins, proteasome inhibitors, and glucocorticoids (9-11). Similarly, COX-2 inhibitors have also been used to slow the progression of cancer (12,13).

Species of the *Stephania* family are known to exert pharmacological actions. For example, the *Stephania delavayi* Diels. (*S. delavayi* Diels.) extract has been reported to safely activate B cell immunity (14), and biscoclaurine alkaloid cepharanthine isolated from *Stephania cepharantha* Hayata (*S. cepharantha* Hayata) induces apoptosis and G₀/G₁ phase arrest through p15^{INK4B} and p21^{Waf1/Cip1} in KMS-12-PE myeloma cells (15). Tetrandrine, a bisbenzylisoquinoline alkaloid isolated

Correspondence to: Dr Min-Jae Lee, School of Veterinary Medicine, Kangwon National University, Chuncheon-si, Gangwon-do 200-701, Republic of Korea
E-mail: mjlee@kangwon.ac.kr

Dr Sung-Won Kwon, CHA Bundang Medical Center, CHA University, Bundang-gu, Seongnam-si, Gyeonggi-do 463-712, Republic of Korea
E-mail: wizard95@cha.ac.kr

*Contributed equally

Key words: *Stephania delavayi* Diels., breast carcinomas, apoptosis, nuclear factor κ B, COX-2

from the root of *Stephania tetrandra* S. Moore (*S. tetrandra* S. Moore), induces G₁ arrest in human colon carcinoma HT29 cells by down-regulating E2F1 and up-regulating p53/p21^{Waf1/Cip1} (16). In addition, the bisbenzylisoquinoline alkaloids cepharanthine, berbamine, and isotetrandrine isolated from *S. cepharantha* Hayata inhibit arachidonic acid-induced inflammation in mice (17).

S. delavayi Diels. is a promising new anticancer therapeutic agent candidate. This herb has been used in traditional Chinese medicine to relieve pain and treat acute gastroenteritis. In addition, *S. delavayi* Diels. is a component of a herbal mixture PC-SPES, which has been used to treat prostate cancer via its estrogenic mechanism of action (18) and has been shown to inhibit MCF-7 cell proliferation by inducing apoptosis and cell cycle arrest (19). However, the molecular mechanisms underlying the *S. delavayi* Diels. anticancer properties have not yet been elucidated.

In the present study, we evaluated the effects of *S. delavayi* Diels. on NF- κ B and COX-2 in breast carcinomas. In an effort to elucidate the molecular and functional basis of its anti-inflammatory and anticancer effects, we found that *S. delavayi* Diels. promotes apoptosis by activating p38 MAPK and inhibiting NF- κ B phosphorylation and COX-2 expression. Our findings provide additional evidence in support of a future use for *S. delavayi* Diels. as a preventative or therapeutic agent against breast cancer.

Materials and methods

Preparation of *S. delavayi* Diels. extract. *S. delavayi* Diels. extract, which was acquired from the International Biological Material Research Center (Daejeon, Korea), was collected on Mt. Bijia, Anning, Yunnan, China.

Standardization of *S. delavayi* Diels. was performed by thin layer chromatography (Polygram[®] Sil G/UV254, 20 x 20 cm, 0.2 mm thick; Macherey-Nagel GmbH & Co. KG, Düren, Germany) with the eluent methylene chloride/methanol/H₂O (70:27:3). Analytical HPLC was performed using a Waters 2695 Separations Module system (Waters Corp., MA, USA) with the Waters photodiode array detector 2996 (variable wavelength UV) and a C18 column (YMC-Pack Pro, C18, S-5 μ m, 12 nm, 4.6 i.d. x 250 mm; YMC Co., Ltd., Kyoto, Japan). We used a gradient elution of 0.05% trifluoroacetic acid in acetonitrile/0.05% trifluoroacetic acid in H₂O at a flow rate of 0.7 ml/min (10–40% aqueous acetonitrile, 60 min). Each fraction was examined for alkaloids with Dragendorff reagent.

Cell culture. The human breast cancer cell lines MDA-MB-231 and MCF-7 were obtained from the Korean Cell Line Bank (Seoul, Korea). Cells were cultivated in RPMI-1640 containing 10% fetal bovine serum, 2 mg/ml sodium bicarbonate, 100 U/ml penicillin, and 100 μ g/ml streptomycin (Gibco-BRL, NY, USA).

Cell viability assay. Cells were seeded in 96-well plates (1.5x10⁴ cells/well) in triplicate and treated with 1, 2, 4, 8, or 16 μ g/ml *S. delavayi* Diels. 12–24 h after plating; control cells were treated with the 0.1% DMSO vehicle alone. Cell proliferation was analyzed 24 and 48 h later using the CCK-8

cell counting kit (Dojindo Molecular Technologies, Inc., Tokyo, Japan) according to the manufacturer's instructions.

Chemosensitivity assay. The chemosensitivity assay was performed using the CytoSelect[™] 96-well *in vitro* tumor sensitivity assay (Cell Biolabs, Inc., CA, USA) according to the manufacturer's protocol.

Apoptosis detection by Annexin V staining. Cells were treated with 4–50 μ g/ml *S. delavayi* Diels. 24 h after plating. After incubation for 24 or 48 h, cells were harvested, washed, and resuspended. FITC-conjugated Annexin V and propidium iodide (PI) 5 μ l each, were added to the cells, followed by addition of binding buffer, and the Annexin V-stained cells were analyzed with BD FACScan (Becton-Dickinson, NJ, USA).

Protein extraction and Western blot analysis. Harvested cells were washed, and total proteins were prepared with the PRO-PREP[™] protein extraction kit (iNtRON Biotechnology, Seongnam, Korea). Equal amounts of protein were loaded, separated by 10% SDS and then transferred to a nitrocellulose membrane in Trans-Blot[®] Transfer Medium (Bio-Rad). Proteins were detected with the following primary antibodies: phospho-p38 MAPK (Cell Signaling Technology, Inc., MA, USA, cat #9215), phospho-SAPK/JNK (Cell Signaling Technology, Inc., cat #9251), phospho-AKT (Cell Signaling Technology, Inc., cat #4060 and cat #2965), NF- κ B (Cell Signaling Technology, Inc., cat #4764), COX-2 (Cayman Chemical, MI, USA, cat #CAY-160106), β -actin (Sigma-Aldrich, MO, USA; cat #A-5316). A horseradish peroxidase-conjugated goat anti-rabbit IgG (Cayman Chemical, cat #10004301) was used as the secondary Ab. Antibody-stained bands were analyzed using the ECL detection kit (Amersham Biosciences, Buckinghamshire, UK).

Fast activated cell-based enzyme-linked immunosorbent assay. Phosphorylation of NF- κ B in each cell which was incubated with 4–8 μ g/ml *S. delavayi* Diels. for 1 or 3 h was determined using the FACE[™] NF- κ B p65 Profiler (Active Motif, CA, USA) according to the manufacturer's protocol.

NF- κ B translocation assay. Attached cells were treated with *S. delavayi* Diels. (4 μ g/ml for MDA-MB-231 cells; 5 μ g/ml for MCF-7 cells) or vehicle alone and incubated for 1 or 3 h in a Lab-Tek[®] II Chamber Slide[™] System (Nalge Nunc International, NY, USA). Cells were washed twice in cold PBS, fixed with cold acetone, and washed again three times in PBS. The fixed cells were incubated overnight with anti-NF- κ B rabbit antibody (Cell Signaling Technology, Inc.), followed by two washes in PBS. Cells were then incubated for 1 h with goat anti-rabbit IgG FITC (Cayman Chemical) followed by 7 μ g/ml bisbenzimidazole H 33342 trihydrochloride (Sigma-Aldrich) for nuclear staining, and photographed using an LSM 510 Meta Fluorescent Microscope with Plan-Apochromat 100x/1.4 Oil DIC (Carl Zeiss, Jena, Germany).

Immunocytochemical detection of COX-2. After treatment with *S. delavayi* Diels. or vehicle alone, attached cells were incubated for 24 or 48 h in a Lab-Tek II Chamber Slide system.




Figure 1. Fingerprint profiles of *Stephania delavayi* Diels. extracts. The UV spectra (A) and chromatogram (B) of typical compounds in peak group 1-6 are shown at upside. HPLC conditions, YMC-Pack Pro C18 column (4.6 x 250 mm, 5 μ m). Mobile phases were of 0.05% trifluoroacetic acid in acetonitrile and 0.05% trifluoroacetic acid in water with gradient elution as 10-40% aqueous acetonitrile at a flow rate of 0.7 ml/min, wavelength, 200-400 nm.

Cells were washed twice in cold PBS, fixed with cold acetone, and washed again three times in PBS. Fixed cells were incubated overnight with anti-COX-2 monoclonal antibody (Biocare Medical, CA, USA), followed by two washes in PBS. Cells were reacted with EnVision™ + reagent (Dako, Glostrup, Denmark), developed with the Liquid DAB substrate chromogen system (Dako), counterstained, and photographed using Axio Observer A1 (Carl Zeiss).

Human tumor xenografts. Thirty-one 8-week-old female Crl:NU/NU-nu mice were purchased from OrientBio (Seongnam, Korea) and acclimated for 7 days in an environment controlled for temperature and relative humidity ($22 \pm 3^\circ\text{C}$, 12-h light/dark cycle). The mice were provided a Purina diet (Seongnam, Korea) and water *ad libitum*. After acclimation, the mice were subcutaneously injected with 5×10^6 MDA-MB-231 cells into each flank. When the tumor volume reached 100-150 mm^3 , mice were randomly assigned to one of four treatment groups. The first group (control; $n=7$) received the 0.1% DMSO vehicle. The second group ($n=8$) received 10 mg/kg paclitaxel by intraperitoneal injection once per week (Sigma-Aldrich); the third group ($n=8$) received daily 10 mg/kg intraperitoneal injections of *S. delavayi* Diels., and the fourth group ($n=8$) received both 10 mg/kg paclitaxel once a week

and 10 mg/kg *S. delavayi* Diels. daily intraperitoneally. During the 24-day treatment period, tumors were measured with a caliper in two dimensions every 3 days; tumor volumes were calculated as $axb^2/2$, where a was the widest point of the tumor and b was the tumor width perpendicular to a. The human tumor xenograft study had been approved by the Institute of Animal Care and Use Committee of the Kangwon National University before performing the experiments.

Statistical analysis. Results are expressed as the mean \pm SD. Groups were compared using the Tukey's studentized range (HSD) test; $p < 0.01$ was considered significant.

Results

***S. delavayi* Diels. extract effectively inhibits breast cancer cell proliferation.** To confirm the quality of the *S. delavayi* Diels., the extracts (6 batches) used in each experiment were analyzed by the HPLC-DAD method (Fig. 1). Mean retention times of the six characteristic peaks were 7.386, 13.825, 21.901, 30.791, 31.959 and 34.078 min. HPLC chromatogram analysis showed that the maximum UV light absorbance of each peak was similar and each fraction reacted with Dragendorff reagent, suggesting that the properties of the *S. delavayi* Diels. extracts




Figure 2. Inhibition of breast carcinoma cell proliferation by *Stephania delavayi* Diels. (*S. delavayi* Diels.) (A) *S. delavayi* Diels. inhibits proliferation of MDA-MB-231 and MCF-7 cells in a dose- and time-dependent manner. (B) *S. delavayi* Diels. inhibits colony formation of MDA-MB-231 and MCF-7 cells. (C) *S. delavayi* Diels. induces cell death in MDA-MB-231 cells. Apoptotic cells increased in a time- and dose-dependent manner in MDA-MB-231 cells. At 24 h, control cells exhibited 15.0% apoptosis, and cells treated with 4 and 40 μg/ml *S. delavayi* Diels. exhibited an increase in apoptosis up to 20.0 and 30.9%, respectively. The population of apoptotic cells reached 44.6% after 48-h treatment with 40 μg/ml *S. delavayi* Diels. (D) *S. delavayi* Diels. induces cell death in MCF-7. Apoptotic cells increased in a time- and dose-dependent manner in the MCF-7 cell line. At 24 h, control cells exhibited 14.4% apoptosis and cells treated with 5 and 50 μg/ml *S. delavayi* Diels. exhibited an increase in apoptosis up to 16.0 and 20.4%, respectively. The population of apoptotic cells reached 43.4% in MCF-7 cells after 48-h treatment with 50 μg/ml *S. delavayi* Diels.

used in each experiment were identical and HPLC-DAD facilitates the determination of the chemical constituents of *S. delavayi* Diels. samples.

To evaluate the anticancer therapeutic potential of *S. delavayi* Diels., we treated cells with increasing doses of *S. delavayi* Diels. and observed cell proliferation at various time points. We found that *S. delavayi* Diels. inhibited cell proliferation in a dose- and time-dependent manner (Fig. 2A and B). At 48 h, the half maximal inhibitory concentration (IC_{50}) was ~4 μg/ml for MDA-MB-231 cells and 5 μg/ml for MCF-7 cells.

To characterize the mechanism underlying the inhibition of cell proliferation, flow cytometry was used to monitor apoptosis in MDA-MB-231 and MCF-7 cells stained with PI and Annexin V-FITC. Treatment with *S. delavayi* Diels. dramatically increased the number of Annexin V-stained and PI/Annexin V-stained cells in a dose- and time-dependent manner (Fig. 2C and D). At 24 h, apoptosis in cells treated with 4 and 40 μg/ml *S. delavayi* Diels. was increased to 20.0 and 30.9% in MDA-MB-231 cells, while with 5 and 50 μg/ml apoptosis was increased to 16.0 and 20.4% in MCF-7 cells, respectively. In contrast, apoptosis in control cells was 15.0% (MDA-MB-231) and 14.4% (MCF-7). Apoptosis was highest after a 48-h treatment with 40 or 50 μg/ml *S. delavayi* Diels. (MDA-MB-231, 44.6%; MCF-7, 43.4%). The IC_{50} of paclitaxel at

72 h for MDA-MB-231 cells has been reported as 1-0.01 μg/ml, and ~27% of the cells were apoptotic at 24 h (20); the IC_{50} of paclitaxel at 48 h for MCF-7 cells was reported as 0.24 μg/ml (21). Thus, the apoptotic effects of *S. delavayi* Diels. in MDA-MB-231 and MCF-7 cells is similar to that of paclitaxel, suggesting the potential of *S. delavayi* Diels. as an anticancer drug candidate.

S. delavayi Diels. inactivates NF-κB through p38 MAPK phosphorylation. NF-κB, a well-known survival factor in cancer cells, transcriptionally regulates COX-2 expression (22), and is regulated in turn by p38 MAPK (2,23,24). We evaluated the effect of *S. delavayi* Diels. on p38 MAPK phosphorylation by Western blot analysis, and determined the effect on NF-κB activity in MDA-MB-231 cells using an in-cell immunosorbent assay that calculates the ratio of phosphorylated NF-κB (Ser486) to total NF-κB.

We examined the effect of *S. delavayi* Diels. on important regulators of programmed cell death, including phospho-Akt (Ser473 and Thr308), the MAPK pathway (phospho-p38 MAPK and phospho-JNK), and their downstream target NF-κB (phospho-NF-κB). We found that *S. delavayi* Diels. treatment induced p38 MAPK phosphorylation but did not alter Akt and JNK phosphorylation (data not shown). Phosphorylation of p38




Figure 3. *Stephania delavayi* Diels. resulted in NF- κ B inactivation via p38 MAPK activation/phosphorylation. (A) *S. delavayi* Diels. increased phosphorylated p38 MAPK in a time- and dose-dependent manner. (B) *S. delavayi* Diels. inhibits NF- κ B phosphorylation. The ratio of phospho-NF- κ B /total NF- κ B protein was reduced by *S. delavayi* Diels. treatment in a dose-dependent manner in MDA-MB-231 cells. In both MDA-MB-231 (C) and MCF-7 (D) cells, NF- κ B protein levels significantly decreased in the nucleus following 1-h and 3-h treatment with the IC₅₀ concentration of *S. delavayi* Diels. FITC-labeled NF- κ B proteins were visualized in the nucleus and cytoplasm of control cells but were observed at very low levels in the nucleus of *S. delavayi* Diels.-treated cells. *p<0.05 and ***p<0.001 compared to control (Tukey's studentized range test).




Figure 4. Inhibition of COX-2 expression by *Stephania delavayi* Diels. (A) Immunocytochemical analysis using a COX-2 antibody. Dark brown color represents COX-2 protein in the cytoplasm; nuclei are stained blue. COX-2 protein expression was dramatically decreased by *S. delavayi* Diels. treatment in both MDA-MB-231 and MCF-7 cells. (B) Western blot analysis using a COX-2 antibody. In both MDA-MB-231 and MCF-7 cells, *S. delavayi* Diels. decreased COX-2 levels in a dose- and time-dependent manner.

MAPK was detected beginning at 45 min in both MDA-MB-231 and MCF-7 cells treated respectively with 40 and with 10 μg/ml *S. delavayi* Diels.; phosphorylation was further increased after 45 and 60 min in both MDA-MB-231 and MCF-7 cells (Fig. 3A). Activation of p38 MAPK by *S. delavayi* Diels. was both dose- and time-dependent.

S. delavayi Diels. also decreased NF-κB phosphorylation in a dose- and time-dependent manner (Fig. 3B). NF-κB phosphorylation is required for entry into the nucleus, where it functions as a transcription factor; thus, nuclear translocation

of NF-κB was investigated in MDA-MB-231 and in MCF-7 using an immunofluorescence assay. We found that *S. delavayi* Diels. inhibited NF-κB nuclear translocation (Fig. 3C and D).

From these observations, we conclude that the NF-κB pathway is an important target of *S. delavayi* Diels. in the induction of cancer cell death.

S. delavayi Diels. negatively regulates COX-2 expression. COX-2 is activated in inflammation and by precancerous and cancerous tissues, and the COX-2 inhibitor sodium salicylate




Figure 5. *Stephania delavayi* Diels. inhibits cancer cell growth in a mouse xenograft model. After 21 days, the mean tumor volumes of treated groups were smaller than that of the control group. *S. delavayi* Diels. inhibited tumor growth to an extent similar to that of paclitaxel.

is an anticancer drug candidate (25,26). For this reason, we hypothesized that COX-2 is a potential target of *S. delavayi* Diels. Immunocytochemical analysis was carried out to determine the effect of *S. delavayi* Diels. on COX-2 expression in MDA-MB-231 and MCF-7 cells. We found that COX-2 expression was lower in *S. delavayi* Diels.-treated cells than in control cells (Fig. 4A). Quantitative Western blot analysis showed that *S. delavayi* Diels. reduced COX-2 protein expression in a dose- and time-dependent manner (Fig. 4B). In MDA-MB-231 cells, a 24-h treatment with 4 μ g/ml *S. delavayi* Diels. reduced COX-2 expression by ~50%, and a 48-h treatment with 40 μ g/ml extract completely abolished COX-2 protein expression. A similar pattern of COX-2 expression was observed in *S. delavayi* Diels.-treated MCF-7 cells. These results suggest that *S. delavayi* Diels. blocks COX-2 expression by inhibiting NF- κ B phosphorylation and blocking nuclear translocation.

Since *S. delavayi* Diels. activated p38 MAPK phosphorylation and inhibited both NF- κ B phosphorylation and COX-2 expression, the primary pathway targeted by *S. delavayi* Diels. is likely to be the p38 MAPK/NF- κ B/COX-2 pathway.

S. delavayi Diels. inhibits cancer cell growth in a mouse xenograft model. To further assess the properties of *S. delavayi* Diels., we used a mouse xenograft model to directly test its antitumor effects. After 21 days of treatment, the mean tumor volumes of all treated groups were lower than that of the control. *S. delavayi* Diels. inhibited tumor growth to an extent similar to paclitaxel (Fig. 5). In addition, oral administration of *S. delavayi* Diels. (50 mg/kg/day for 7 days) produced no

evidence of toxicity, suggesting that this compound may be used safely (data not shown) (14). No differences in liver function tests, including complete blood cell count and serum enzyme levels, were observed between the drug treatment groups and the control group, and no histopathological changes were observed in any group. Taken together, our findings suggest that *S. delavayi* Diels. is a promising anticancer drug candidate that has a broad pharmaceutical range.

Discussion

Although epidemiologic studies have reported that vegetable-based diets decrease both the incidence and morbidity of cancer, the mechanisms of action are unclear and are therefore under investigation. For instance, Nexrutine, a herbal extract derived from *Phellodendron amurense*, has been investigated for its effects against prostate cancer (27,28). Our group is particularly interested in herbs used in traditional East Asian medicine, and *S. delavayi* Diels. has long been used as an anti-inflammatory and analgesic therapy in China. There are many obstacles in developing a plant extract as a cancer therapy. For example, identifying the active components and their mechanisms of action is difficult because plant extracts are complex, sometimes containing hundreds of compounds. However, to advance the use of botanicals as cancer preventive agents, it is necessary to evaluate their ability to inhibit cancer cell proliferation and to characterize their mechanism of action.

Our results demonstrate that *S. delavayi* Diels. effectively inhibits proliferation of MDA-MB-231 and MCF-7 by inducing

cell death. We found that *S. delavayi* Diels. induces p38 MAPK phosphorylation, down-regulates NF- κ B phosphorylation, suppresses NF- κ B nuclear translocation, and decreases protein expression of the downstream target COX-2. The NF- κ B signaling pathway promotes tumorigenesis and progression (3) by inhibiting apoptosis (4) and inducing G1/S phase transition (5). It is controversial because the effect (i.e., activation or inactivation) of activated p38 MAPK on its downstream target NF- κ B depends on cell type, environmental conditions, and the substance activating p38 MAPK (23-25,29). However *S. delavayi* Diels. appears clearly to prevent carcinogenesis and tumor progression by inactivating NF- κ B similar to sodium salicylate which induces apoptosis through p38 MAPK phosphorylation/NF- κ B inactivation (25).

NF- κ B activation produces differential effects according to the cell phenotype. NF- κ B activation inhibits apoptosis (30,31) and apoptosis-related protein-3 which changes during development and inflammation (32), and suppresses TNF- α -induced apoptosis by inducing transcription of Bcl-2, an inhibitor of apoptosis, and TNF receptor-associated factor 1 and 2 (33-35). However, NF- κ B activation can also stimulate apoptosis, as evidenced by doxorubicin-mediated induction of cell death through I κ B degradation in N-type neuroblastoma cells (36) and p53-mediated apoptosis through NF- κ B activation (37).

Many signaling pathways modulate the phosphorylation of the RelA/p65 subunit of NF- κ B. For instance, p38 MAPK attenuates the effects of NF- κ B, thereby suppressing Fas expression (38). In addition, GSK-3 β -regulated p65 phosphorylation at Ser468 enhances its transactivation potential (39), JNK down-regulates NF- κ B phosphorylation (40), and protein kinase A induction of p65 phosphorylation at Ser276 regulates DNA binding and oligomerization (41). We found that phosphorylation of p38 MAPK changed in a dose- and time-dependent manner after *S. delavayi* Diels. treatment but Akt and JNK phosphorylation were not affected. In addition, NF- κ B phosphorylation decreased in a dose-dependent manner beginning at 60 min (Fig. 2B). These results suggest crosstalk between NF- κ B and p38, as well as the dephosphorylation of NF- κ B by p38 MAPK. However, other pathways that down-regulate NF- κ B phosphorylation, including GSK-3 β , c-raf, protein kinase A, phosphatase and tensin homolog, and signaling cascades upstream of p38 MAPK require further study. We presented evidence of the effect of *S. delavayi* Diels. on MDA-MB-231 and MCF-7 cells; however, *S. delavayi* Diels. requires further evaluation in additional cancer cell lines due to the complex effects of NF- κ B.

Our results demonstrate that *S. delavayi* Diels. induces cell death primarily by increasing p38 MAPK phosphorylation, thereby suppressing NF- κ B-mediated transcription of COX-2. Through these processes, *S. delavayi* Diels. induced apoptosis to inhibit cell proliferation in MDA-MB-231 and MCF-7 cells. *S. delavayi* Diels. appears to effectively target a relatively specific pathway, and its use has been reported as safe (14), with relatively low toxicity compared to small molecule inhibitors of COX-2 such as celecoxib, which has numerous side effects including gastrointestinal bleeding (42). Its long history of use in traditional Chinese medicine also provides evidence for its safety.

In the present study, we showed that *S. delavayi* Diels. acts on the p38 MAPK and NF- κ B pathways *in vitro* and inhibits

cancer cell growth in an animal model. The use of *S. delavayi* Diels. as an anticancer drug must be validated and characterized in more detail. Nevertheless, our current knowledge of its mechanism of action, toxicity, and efficacy indicate that *S. delavayi* Diels. has great therapeutic potential.

Acknowledgements

This study was supported by grants from the Ministry of Education, Science and Technology (MEST) of Korea to the Korea Institute of Oriental Medicine (G07080, K08141), from BioGreen 21 (#20070303034044), and partially from the National Cancer Center (NCC-1110060).

References

1. Cano E and Mahadevan LC: Parallel signal processing among mammalian MAPKs. *Trends Biochem Sci* 20: 117-122, 1995.
2. Herlaar E and Brown Z: p38MAPK signaling cascades in inflammatory disease. *Mol Med Today* 5: 439-447, 1999.
3. Luo JL, Kamata H and Karin M: IKK/NF-kappaB signaling: balancing life and death, a new approach to cancer therapy. *J Clin Invest* 115: 2625-2632, 2005.
4. Sun XF and Zhang H: NF κ B and NF κ BI polymorphisms in relation to susceptibility of tumour and other diseases. *Histol Histopathol* 22: 1387-1398, 2007.
5. Monks NR, Biswas DK and Pardee AB: Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-kappaB as a target. *J Cell Biochem* 92: 646-650, 2004.
6. St-Germain ME, Gagnon V, Parent S and Asselin E: Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway. *Mol Cancer* 3: 7, 2004.
7. Monks NR and Pardee AB: Targeting the NF-kappaB pathway in estrogen receptor negative MDA-MB-231 breast cancer cells using small inhibitory RNAs. *J Cell Biochem* 98: 221-233, 2006.
8. Jang BC, Sanchez T, Schaefer HJ, *et al*: Serum withdrawal-induced post-transcriptional stabilization of cyclooxygenase-2 mRNA in MDA-MB-231 mammary carcinoma cells requires the activity of the p38 stress-activated protein kinase. *J Biol Chem* 275: 39507-39515, 2000.
9. Karin M, Yamamoto Y and Wang QM: The IKK NF-kappa B system: a treasure trove for drug development. *Nat Rev Drug Discov* 3: 17-26, 2004.
10. Orlowski RZ and Baldwin AS Jr: NF-kappaB as a therapeutic target in cancer. *Trends Mol Med* 8: 385-389, 2002.
11. Guttridge DC, Albanese C, Reuther JY, *et al*: NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. *Mol Cell Biol* 19: 5785-5799, 1999.
12. Dannenberg AJ, Altorki NK, Boyle J, *et al*: Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. *Lancet Oncol* 2: 544-551, 2001.
13. Thun MJ, Henley SJ and Patrono C: Non-steroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. *J Natl Cancer Inst* 94: 252-266, 2002.
14. Park DH, Li YC, Shim J, *et al*: Biological safety and B cells activation effects of *Stephania delavayi* Diels. *Mol Cell Toxicol* 5: 93-98, 2009.
15. Kikukawa Y, Okuno Y, Tatetsu H, *et al*: Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a biscoclaurine alkaloid. *Int J Oncol* 33: 807-814, 2008.
16. Meng LH, Zhang H, Hayward L, *et al*: Tetrandrine induces early G1 arrest in human colon carcinoma cells by down-regulating the activity and inducing the degradation of G1-S-specific cyclin-dependent kinases and by inducing p53 and p21^{Cip1}. *Cancer Res* 64: 9086-9092, 2004.
17. Yasukawa K, Akasu M, Takeuchi M, *et al*: Bisbenzylisoquinoline alkaloids inhibit tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin. *Oncology* 50: 137-140, 1993.
18. DiPaola RS, Zhang H, Lambert GH, *et al*: Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. *N Engl J Med* 339: 785-791, 1998.

19. Halicka H, Ardelt B, Juan G, *et al*: Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC SPES. *Int J Oncol* 11: 437-448, 1997.
20. Serrano MJ, Sanchez-Rovira P, Algarra I, *et al*: Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines. *Jpn J Cancer Res* 93: 559-566, 2002.
21. Merlin JL, Barberi-Heyob M and Bachman N: In vitro comparative evaluation of trastuzumab (Herceptin[®]) combined with paclitaxel (Taxol[®]) or docetaxel (Taxotere[®]) in HER2-expressing human breast cancer cell lines. *Ann Oncol* 13: 1743-1748, 2002.
22. Tsatsanis C, Androulidaki A, Venihaki M, *et al*: Signalling networks regulating cyclooxygenase-2. *Int J Biochem Cell Biol* 38: 1654-1661, 2006.
23. Sakai N, Wada T, Furuichi K, *et al*: p38MAPK phosphorylation and NF- κ B activation in human crescentic glomerulonephritis. *Nephrol Dial Transplant* 17: 998-1004, 2002.
24. Alpert D, Schwenger P, Han J, *et al*: Cell stress and MKK6b-mediated p38MAP kinase activation inhibit tumor necrosis factor-induced I κ B phosphorylation and NF- κ B activation. *J Biol Chem* 274: 22176-22183, 1999.
25. Schwenger P, Bellosta P, Vietor I, *et al*: Sodium salicylate induces apoptosis via 38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. *Proc Natl Acad Sci USA* 94: 2869-2873, 1997.
26. Kwon KS and Chae HJ: Sodium salicylate inhibits expression of COX-2 through suppression of ERK and subsequent NF- κ B activation in rat ventricular cardiomyocytes. *Arch Pharm Res* 26: 545-553, 2003.
27. Kumar AP, Bhaskaran S, Ganapathy M, *et al*: Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. *Clin Cancer Res* 13: 2784-2794, 2007.
28. Ghosh R, Garcia GE, Crosby K, *et al*: Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. *Neoplasia* 9: 893-899, 2007.
29. Goebeler M, Gillitzer R, Kilian K, *et al*: Multiple signaling pathways regulate NF- κ B-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells. *Blood* 97: 46-55, 2001.
30. van Hogerlinden M, Rozell BL and Ahrlund-Richter L, *et al*: Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. *Cancer Res* 59: 3299-3303, 1999.
31. Miyamoto S, Maki M, Schmitt MJ, *et al*: Tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha is a signal for its degradation but not dissociation from NF-kappaB. *Proc Natl Acad Sci USA* 91: 12740-12744, 1994.
32. Yang G, Yu F, Fu H, *et al*: Identification of the distinct promoters for the two transcripts of apoptosis related protein 3 and their transcriptional regulation by NFAT and NFkappaB. *Mol Cell Biochem* 302: 187-194, 2007.
33. Herrmann JL, Beham AW, Sarkiss M, *et al*: Bcl-2 suppresses apoptosis resulting from disruption of the NF-kappaB survival pathway. *Exp Cell Res* 237: 101-109, 1997.
34. Notarbartolo M, Poma P, Perri D, *et al*: Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF- κ B activation levels and in IAP gene expression. *Cancer Lett* 224: 53-65, 2005.
35. Wang CY, Mayo MW, Korneluk RG, *et al*: NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. *Science* 281: 1680-1683, 1998.
36. Bian X, McAllister-Lucas LM, Shao F, *et al*: NF-kappaB activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. *J Biol Chem* 276: 48921-48929, 2001.
37. Ryan KM, Ernst MK, Rice NR, *et al*: Role of NF-kappaB in p53-mediated programmed cell death. *Nature* 404: 892-897, 2000.
38. Ivanov VN and Ronai Z: Down-regulation of tumor necrosis factor alpha expression by activating transcription factor 2 increases UVC-induced apoptosis of late-stage melanoma cells. *J Biol Chem* 274: 14079-14089, 1999.
39. Schwabe RF and Brenner DA: Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. *Am J Physiol Gastrointest Liver Physiol* 283: G204-G211, 2002.
40. Park MK, Hwang SY, Kim JO, *et al*: NS398 inhibits the growth of Hep3B human hepatocellular carcinoma cells via caspase-independent apoptosis. *Mol Cells* 17: 45-50, 2004.
41. Zhong H, SuYang H, Erdjument-Bromage H, *et al*: The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. *Cell* 89: 413-424, 1997.
42. Chan FK, Hung LC, Suen BY, *et al*: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. *N Engl J Med* 347: 2104-2110, 2002.